Advertisement
Document › Details
Epigenomics AG. (11/29/17). "Press Release: Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive Vice President Finance and a Member of the Management Board (Vorstand)". Berlin & Germantown, MD.
Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced today that the Supervisory Board appointed Albert Weber Executive Vice President of Finance effective January 1, 2018. Mr. Weber, who has worked at Epigenomics for the past seventeen years, will become a member of the Executive Board of Epigenomics and continue to oversee the company’s financial, accounting and controlling departments.
Mr. Weber (54), has more than 25 years of corporate finance experience including the last seventeen years at Epigenomics. Prior to this recent appointment Mr. Weber was the Senior Vice President of Finance, Accounting and Controlling for Epigenomics. Prior to joining the company, Albert served as Manager Controlling of Pironet AG, a Cologne based IT start-up and previously at EMI Group Germany as the Manager Treasury and Corporate Accounting. Mr. Weber has experience in capital raises, all corporate finance functions and IPO’s. He has a degree in Business Administration from Cologne University and is certified in IFRS accounting.
Heino von Prondzynski, Chairman of the Supervisory Board, stated: “The Supervisory Board is very happy to recognize Albert’s hard work and dedication to Epigenomics by adding him the Executive Board. Mr. Weber’s financial experience will be a valued benefit to the Executive Board as the company prepares for the next stage of growth.”
“I am excited to join the Executive Board,” said Mr. Weber. “I’ve been with Epigenomics for seventeen years and I’m truly excited about the amazing opportunity in front of the company. I look forward to helping the organization transform the colorectal screening market.”
About Epigenomics
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.
For more information, visit www.epigenomics.com.
Contact:
Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Record changed: 2023-06-05 |
Advertisement
More documents for Epigenomics (Group)
- [1] Epigenomics AG. (7/24/23). "Press Release: Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets". Berlin....
- [2] Epigenomics AG. (2/15/23). "Press Release: Epigenomics Decides to Restructure to Minimize Costs". Berlin & San Diego, CA....
- [3] Epigenomics AG. (1/27/23). "Press Release: Resignation of Supervisory Board Chairman Heino von Prondzynski". Berlin....
- [4] InfanDx AG. (8/4/21). "Press Release: Neonatal Diagnostics Company InfanDx AG Appoints Dr. Gunter Weiss as COO". Cologne....
- [5] Epigenomics AG. (10/8/18). "Press Release: Capital Increase through Rights Issue with Subscription Rights of Existing Shareholders [NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAP...
- [6] Epigenomics AG. (8/8/18). "Press Release: Epigenomics AG Announces 2018 Second Quarter and Six Month Financial Results". Berlin & San Diego, CA....
- [7] Epigenomics AG. (7/2/18). "Press Release: Liquid Biopsy Test for Liver Cancer Detection to Obtain CE Mark". Berlin & San Diego, CA....
- [8] Epigenomics AG. (6/11/18). "Press Release: Centers for Medicare & Medicaid Services Publish Preliminary Rate for Epigenomics’ Colorectal Cancer Screening Test Epi proColon". Berlin & Germantown, MD....
- [9] Epigenomics AG. (3/23/18). "Press Release: Epigenomics AG Reports Results for Financial Year 2017". Berlin & Germantown, MD....
- [10] Epigenomics AG. (8/30/17). "Press Release: Epigenomics Commences Post Approval Study on Epi proColon". Berlin & Germantown, MD....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top